Stock listing

Frankfurt:DP8 CervoMed Inc. Aktie

German listing (Frankfurt) of CervoMed Inc. · home listing NASDAQ:CRVO

Follow CervoMed Inc. into a list and get an email when it puts out news.

Share price · FWB:DP8

€1.18 EUR -0.12 (-9.2%)

Close on Nov 20, 2026

Past year -78.2% · daily closes, Nov 20, 2025 – Nov 12, 2026, adjusted for splits
Day range
€1.18 – €1.18 EURNov 20, 2026
Market cap
€17.84M EURAt the close on Nov 20, 2026 · price × 15.12M shares outstanding
52-week range
€1.18 – €8.49 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
€883 EURMedian day 0 shares · 54 days with no trades · last 3 months, Aug 20, 2026 – Nov 12, 2026
CervoMed Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:CRVO · Home$1.46 USD+0.01 (+0.7%)1,183,199$1.53$1.65$1.401$1.45Close on Nov 20, 2026
Frankfurt:DP8€1.18 EUR-0.12 (-9.2%)—€1.18€1.18€1.18€1.30Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 12, 2026 · FWB:DP8 · EUR, adjusted for splits

DayCloseChange%OpenHighLowVolume
€1.601+0.396+32.9%€1.601€1.601€1.6010
€1.205-0.046-3.7%€1.205€1.205€1.2050
€1.251-0.001-0.1%€1.251€1.251€1.2510
€1.252-0.007-0.6%€1.252€1.252€1.2520
€1.259-0.103-7.6%€1.259€1.259€1.2595,290
€1.362+0.029+2.2%€1.362€1.362€1.3620
€1.333-0.086-6.1%€1.333€1.333€1.3330
€1.419+0.022+1.6%€1.419€1.419€1.4190
€1.397-0.131-8.6%€1.397€1.397€1.3970
€1.528-0.441-22.4%€1.528€1.528€1.528800
€1.969+0.027+1.4%€1.969€1.969€1.9695,938
€1.942-0.035-1.8%€1.942€1.942€1.9420
€1.977-0.066-3.2%€1.977€1.977€1.9770
€2.043+0.113+5.9%€2.043€2.043€2.0435,946
€1.93-0.093-4.6%€1.93€1.93€1.930
€2.023+0.02+1.0%€2.023€2.023€2.0230
€2.003-0.012-0.6%€2.003€2.003€2.0030
€2.015+0.051+2.6%€2.015€2.015€2.0150
€1.964-0.003-0.2%€1.964€1.964€1.9640
€1.967-0.067-3.3%€1.967€1.967€1.9670
€2.034+0.063+3.2%€2.034€2.034€2.0340
€1.971-0.234-10.6%€1.971€1.971€1.9710
€2.205-0.62-21.9%€2.205€2.205€2.2050
€2.825-0.05-1.7%€2.825€2.825€2.8250
€2.875+0.102+3.7%€2.875€2.875€2.8757,200
€2.773-0.11-3.8%€2.773€2.773€2.7730
€2.883-0.339-10.5%€2.883€2.883€2.8830
€3.222+0.312+10.7%€2.908€3.227€2.903340
€2.91+0.361+14.2%€2.742€2.929€2.737120
€2.549-0.046-1.8%€2.549€2.549€2.5490
€2.595+0.093+3.7%€2.595€2.595€2.5950
€2.502+0.217+9.5%€2.502€2.502€2.5020
€2.285+0.103+4.7%€2.285€2.285€2.2850
€2.182+0.01+0.5%€2.182€2.182€2.1820
€2.172+0.009+0.4%€2.172€2.172€2.1720
€2.163-0.035-1.6%€2.163€2.163€2.1630
€2.198+0.101+4.8%€2.198€2.198€2.1980
€2.097+0.014+0.7%€2.097€2.097€2.0970
€2.083-0.086-4.0%€2.083€2.083€2.0830
€2.169+0.059+2.8%€2.169€2.169€2.1690
€2.11+0.04+1.9%€2.11€2.11€2.110
€2.07-0.196-8.6%€2.07€2.07€2.070
€2.266+0.073+3.3%€2.266€2.266€2.2660
€2.193+0.084+4.0%€2.193€2.193€2.1930
€2.109-0.008-0.4%€2.109€2.109€2.1090
€2.117-0.031-1.4%€2.117€2.117€2.1170
€2.148+0.021+1.0%€2.148€2.148€2.1480
€2.127-0.01-0.5%€2.127€2.127€2.1270
€2.137+0.009+0.4%€2.137€2.137€2.1370
€2.128-0.11-4.9%€2.128€2.128€2.1280
€2.238+0.063+2.9%€2.238€2.238€2.2380
€2.175-0.045-2.0%€2.175€2.175€2.1750
€2.22+0.009+0.4%€2.22€2.22€2.220
€2.211-0.008-0.4%€2.211€2.211€2.2110
€2.219-0.02-0.9%€2.219€2.219€2.2190
€2.239+0.003+0.1%€2.239€2.239€2.2390
€2.236+0.034+1.5%€2.236€2.236€2.2360
€2.202+0.018+0.8%€2.202€2.202€2.2020
€2.184+0.059+2.8%€2.184€2.184€2.1840
€2.125-0.146-6.4%€2.125€2.125€2.1250
€2.271+0.088+4.0%€2.271€2.271€2.2710

Splits

2 splits since 2022 · FWB:DP8 · every price before a split is adjusted for it

DayRatioWhat
2-for-3Consolidation
1-for-50Consolidation
Ticker
Frankfurt:DP8
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Frankfurt
Currency
EUR

What changed lately

Latest news

All CervoMed Inc. news

CervoMed Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
31 in the last 12 months · 79 in all · newest Nov 16, 2026 · oldest 2023
Decks
16 decks · latest March 2026

Where CervoMed Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:CRVO · Home listingNASDAQUnited StatesUSD
LS Exchange:A3ES01LS ExchangeGermanyEUR
Lang & Schwarz:A3ES01Lang & SchwarzGermanyEUR
BOATS:CRVOBOATSUnited StatesUSD
Tradegate:DP8TradegateGermanyEUR
Frankfurt:DP8 · This pageFrankfurtGermanyEUR
Stuttgart:DP8StuttgartGermanyEUR

Valuation

EV/sales 285× against a median of 46.1×: the highest of 3 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$2.49M USD
P/E
Loss
EV/sales
285×
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
1.3×
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.0×
Beta vs S&P 500
1.97

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
CervoMed Inc. · NASDAQ:CRVOUS$22.09MUS$2.49Mn/a285×n/a1.3×n/a0.0×1.97
Actinogen Medical Limited · ASX:ACWUS$23.08MUS$15.17Mn/an/an/a1.6×n/a0.2×n/a
BioNxt Solutions Inc · CSE:BNXTUS$22.78MUS$22.72Mn/an/an/an/an/an/a0.22
Polyrizon Ltd. · NASDAQ:PLRZUS$22.61MUS$7.56Mn/an/an/a0.9×n/a0.0×0.67
ME Therapeutics Holdings, Inc. · CSE:METXUS$22.25MUS$21.88Mn/an/an/a49.5×n/a0.0×0.52
Sona Nanotech, Inc. · CSE:SONAUS$21.84MUS$22.06Mn/an/an/an/an/an/a0.47
Mendus AB · OMXSTO:IMMUUS$21.76MUS$17.65Mn/an/an/a0.4×n/a0.0×n/a
Metagenomi Therapeutics, Inc. · NASDAQ:MGXUS$21.36M−US$44.10Mn/a−6.2×n/a0.2×n/a0.4×1.65
NanoGroup SA · GPW:NNGUS$21.32MUS$18.78Mn/an/an/a4.0×n/a0.0×n/a
Cel-Sci Corporation · AMEX:CVMUS$21.28MUS$14.76Mn/an/an/a1.9×n/a0.0×1.13
ZYUS Life Sciences Corporation · TSXV:ZYUSUS$20.92MUS$25.65Mn/a98.4×n/an/an/an/a-0.02
Median of the othersUS$21.80MUS$18.22M46.1×1.6×0.0×0.52

Forecasts

6 strong buy · Analysts' consensus from EODHD, read Nov 9, 2026. Not 6ix's view and not investment advice.

Price target
15.00 USD · Analysts' mean
EPS, year to Dec 2026
-2.13 · 5 analysts
Revenue, year to Dec 2026
133.3K · 6 analysts

Team and board

Officers

OfficerRole
John AlamCo-Founder and Chief Executive Officer
William ElderChief Financial Officer and General Counsel
PJ KelleherInvestor Relations
Kelly BlackburnExecutive Vice President, Clinical Development
Marco VerwijsExecutive Vice President, Technical Operations
Mark De RoschExecutive Vice President, Regulatory and Government Affairs, and Program Management
Matthew WintonChief Commercial and Business Officer
Sylvie GrégoireCo-Founder

Board

DirectorRole
Joshua BogerChair Of The Board
David QuigleySenior Partner
Frank ZavrlDirector
Jane H. HollingsworthDirector
Jeff PoultonDirector
John AlamCo-Founder and Chief Executive Officer
Marwan SabbaghDirector
Sylvie GrégoireCo-Founder

Events

QuarterResultsShare move
Q3 2026Nov 6, 2026 · After close+0.7%
Q2 2026Aug 7, 2026+3.6%
Q1 2026May 19, 2026+6.6%
Q4 2025Mar 13, 2026 · After close+1.4%
Q3 2025Nov 7, 2025 · After close−0.3%
Q2 2025Aug 8, 2025 · Before open+5.5%
Q1 2025Jun 13, 2025 · After close+2.0%
Q4 2024Mar 17, 2025 · Before open+40.5%
Q3 2024Nov 12, 2024 · Before open−2.5%
Q2 2024Aug 9, 2024 · After close+7.5%
All 20 quarters
QuarterResultsShare move
Q1 2024May 14, 2024 · After close+0.1%
Q4 2023Mar 29, 2024 · After close−2.6%
Q3 2023Nov 13, 2023 · Before open−1.2%
Q2 2023Aug 8, 2023 · After close−3.5%
Q1 2023May 15, 2023 · Before open−2.2%
Q4 2022Mar 21, 2023−2.5%
Q3 2022Nov 14, 2022+21.5%
Q2 2022Aug 11, 2022−2.0%
Q1 2022May 12, 2022+18.6%
Q4 2021Mar 21, 2022−3.0%

Open Events

Decks

DeckKindSlidesDate
AD/PD 2026Conference18 slidesMarch 2026
CTAD 2025Conference25 slidesDec 4, 2025
Conference Presentation (June 2025)Conference20 slidesJune 2025
Technical Presentation (January 2025)Technical22 slidesJan 31, 2025
Investor Presentation (December 2024)Investor deck13 slidesDec 10, 2024
Investor Presentation (October 2023)Investor deck25 slidesOct 25, 2023
Technical Presentation (October 2023)Technical22 slidesOct 25, 2023
Investor Presentation (September 2023)Investor deck20 slidesSep 6, 2023
Diffusion Pharmaceuticals — Canaccord Growth Conference 2023Conference20 slidesAug 9, 2023
Diffusion Pharmaceuticals — Merger or Acquisition (May 2023)Merger or acquisition26 slidesMay 15, 2023
All 16 decks
DeckKindSlidesDate
EIP Pharma — Merger or Acquisition (March 2023)Merger or acquisition25 slidesMar 30, 2023
Diffusion Pharmaceuticals — Investor Presentation (September 2020)Investor deck29 slidesSep 15, 2020
Diffusion Pharmaceuticals — Technical Presentation (December 2019)Technical25 slidesDec 10, 2019
CTAD 2019Conference19 slidesDecember 2019
Diffusion Pharmaceuticals — Investor Presentation (May 2017)Investor deck40 slidesMay 22, 2017
Diffusion Pharmaceuticals — Investor Presentation (January 2017)Investor deck45 slidesJan 27, 2017

Open Decks

Financings

RaiseDate
Registered direct offering of common stock
Closed: US$10M raised · US$4 a share · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Working capital and general corporate purposes
Jun 22, 2026
Registered direct offering of common stock
Announced: US$10M · US$4 a share · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Working capital and general corporate purposes
Jun 18, 2026
Private placement of units (common stock or pre-funded warrant, Series B warrant and Series C warrant)
Announced: about US$10.5M · US$3.14 a unit · Warrants at US$3.32
Buyers: Joshua S. Boger; Trusts related to John J. Alam and Sylvie Grégoire
Insiders: Supported by insiders including board chair Joshua S. Boger and trusts related to CEO John J. Alam and director Sylvie Grégoire
Use of proceeds: Research and development of neflamapimod, working capital and general corporate purposes
Jun 10, 2026

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue4.01M9.74M7.14M0000
Cost of revenue18.8M8.44M1.34M93.4K103.2K97.9K110.4K68.0K25.3K
Gross profit-9.06M-1.29M-1.34M-93.4K-103.2K-97.9K-110.0K-68.0K-25.3K
Research and development21.8M18.8M8.44M1.34M8.50M9.43M6.62M5.75M5.09M7.25M
Selling, general and administrative10.5M9.17M6.52M8.74M7.45M6.44M5.42M
Operating income-28.3M-18.2M-7.81M-3.48M-24.7M-16.0M-11.6M-19.0M-11.3M-18.4M
Depreciation and amortization1.94M5093.4K103.2K97.9K110.4K68.0K25.3K
EBITDA-16.3M-7.81M-3.48M-24.6M-15.9M-11.5M-18.8M-11.3M-18.3M
Interest expense05873.00K100.0K37.0K
Income before tax-27.0M-16.3M-2.17M-15.6M-24.5M-15.9M-11.5M-18.8M-2.42M-18.4M
Income tax0800.0K0-443.9K-1.68M332.9K-437.3K-1.06M-364.8K
Net income-27.0M-16.3M-2.17M-5.80M-24.1M-14.2M-11.8M-18.4M-1.36M-18.0M
Earnings per share, basic-2.98-2.02-0.82-11.20-12.38-0.30-1.76-8.21-3.16-1.76
Earnings per share, diluted2,038,891.001,946,859.0053,831,973.006,706,509.003,242,301.00-29.11-1.76

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents8.24M9.00M7.79M4.09M37.3M18.5M14.2M7.99M8.90M1.55M
Short-term investments12.6M29.9M012.4M0
Receivables427.0K2.25M915.4K69.6K
Current assets22.9M43.1M9.96M4.16M37.8M18.8M14.6M8.91M9.67M1.60M
Property, plant and equipment0149.2K252.4K350.3K460.7K79.8K
Goodwill06.93M6.93M
Total assets22.9M43.1M9.97M4.16M37.8M27.7M24.1M18.2M26.1M17.5M
Accounts payable1.45M1.51M662.5K97.3K947.5K545.8K1.25M198.8K512.0K1.68M
Current liabilities4.66M3.88M2.60M13.2M2.93M2.44M1.72M804.0K2.69M4.44M
Total debt12.4M10.0M149.2K247.0K550.0K2.43M
Total liabilities4.66M3.88M2.60M13.2M2.93M2.92M3.98M2.59M4.92M8.30M
Shareholders' equity18.2M39.2M7.38M-33.3M34.9M24.8M20.1M15.6M21.2M9.18M
Shares outstanding9.25M8.70M5.67M518.1K2.04M64.0M33.5M3.38M968.0K10.3M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-23.4M-16.5M-7.45M-2.57M-14.5M-13.6M-9.86M-10.8M-12.3M-10.8M
Capital spending0-3-3-10000-447.8K-2.33K
Free cash flow-23.4M-16.5M-7.45M-2.57M-14.5M-13.6M-9.86M-10.8M-12.8M-10.8M
Cash from investing18.1M-28.7M0-12.2M4.00K0-447.8K8.50M
Cash from financing4.59M46.4M11.1M033.3M17.9M16.0M9.87M20.1M1.83M
Change in cash-764.0K1.21M3.70M-2.57M18.8M4.34M6.19M-905.3K7.34M-444.3K

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 19, 2026Insider tradeSEC
8-K · Current reportNov 16, 2026Current reportSEC
8-K · Current reportNov 9, 2026ResultsSEC
10-Q · Quarterly reportNov 6, 2026Quarterly reportSEC
8-K · Current reportOct 29, 2026Current reportSEC
4 · Change in ownershipOct 23, 2026Insider tradeSEC
4 · Change in ownershipOct 23, 2026Insider tradeSEC
4 · Change in ownershipOct 23, 2026Insider tradeSEC
8-K · Current reportOct 14, 2026Current reportSEC
8-K · Current reportOct 13, 2026Current reportSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportOct 9, 2026Current reportSEC
8-K · Current reportSep 28, 2026Current reportSEC
8-K · Current reportSep 10, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
8-K · Current reportAug 10, 2026ResultsSEC
S-8 · Registration statement for employee plansAug 7, 2026Offer documentSEC
10-Q · Quarterly reportAug 7, 2026Quarterly reportSEC
8-K · Current reportAug 4, 2026Current reportSEC
8-K · Current reportJul 14, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveJul 13, 2026Other filingsSEC
424B3 · ProspectusJul 10, 2026Offer documentSEC
8-K · Current reportJul 9, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 8, 2026Big-stake noticeSEC
S-3 · Registration statementJul 6, 2026Offer documentSEC
SCHEDULE 13G · Big-stake noticeJun 26, 2026Big-stake noticeSEC
8-K · Current reportJun 22, 2026Current reportSEC
424B5 · ProspectusJun 22, 2026Offer documentSEC
8-K · Current reportJun 18, 2026Material contractSEC
8-K · Current reportJun 18, 2026Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedJun 15, 2026Big-stake noticeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
8-K · Current reportJun 15, 2026Current reportSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
8-K · Current reportJun 10, 2026Material contractSEC
8-K · Current reportJun 9, 2026Meeting outcomeSEC
8-K · Current reportMay 18, 2026ResultsSEC
10-Q · Quarterly reportMay 15, 2026Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 11, 2026Big-stake noticeSEC
ARS · Annual report to shareholdersApr 30, 2026Annual reportSEC
DEF 14A · Proxy statementApr 30, 2026Meeting noticeSEC
8-K · Current reportApr 22, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 7, 2026Big-stake noticeSEC
8-K · Current reportApr 7, 2026Current reportSEC
8-K · Current reportMar 23, 2026Current reportSEC
8-K · Current reportMar 19, 2026Current reportSEC
8-K · Current reportMar 17, 2026ResultsSEC
10-K · Annual reportMar 13, 2026Annual reportSEC
8-K · Current reportMar 4, 2026Current reportSEC
8-K · Current reportFeb 18, 2026Current reportSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeFeb 11, 2026Big-stake noticeSEC
8-K · Current reportJan 8, 2026Current reportSEC
4 · Change in ownershipDec 5, 2025Insider tradeSEC
3 · Initial statement of ownershipDec 5, 2025Insider tradeSEC
8-K · Current reportDec 5, 2025Current reportSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
4 · Change in ownershipNov 17, 2025Insider tradeSEC
4 · Change in ownershipNov 17, 2025Insider tradeSEC
4 · Change in ownershipNov 17, 2025Insider tradeSEC
4 · Change in ownershipNov 13, 2025Insider tradeSEC
4 · Change in ownershipNov 13, 2025Insider tradeSEC
4 · Change in ownershipNov 13, 2025Insider tradeSEC
8-K · Current reportNov 10, 2025ResultsSEC
S-8 · Registration statement for employee plansNov 7, 2025Offer documentSEC
10-Q · Quarterly reportNov 7, 2025Quarterly reportSEC
8-K · Current reportNov 4, 2025Current reportSEC
8-K · Current reportOct 29, 2025Management or board changeSEC
8-K · Current reportOct 22, 2025Current reportSEC
8-K · Current reportOct 8, 2025Current reportSEC
4 · Change in ownershipOct 8, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 8, 2025Insider tradeSEC
UPLOAD · Letter from the SECSep 24, 2025Other filingsSEC
CORRESP · Letter to the SECSep 23, 2025Other filingsSEC
UPLOAD · Letter from the SECSep 12, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 20, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
8-K · Current reportAug 11, 2025ResultsSEC
10-Q · Quarterly reportAug 8, 2025Quarterly reportSEC
8-K · Current reportAug 5, 2025Current reportSEC
8-K · Current reportJul 28, 2025Current reportSEC
8-K · Current reportJun 25, 2025Meeting outcomeSEC
4 · Change in ownershipJun 25, 2025Insider tradeSEC
4 · Change in ownershipJun 25, 2025Insider tradeSEC
4 · Change in ownershipJun 25, 2025Insider tradeSEC
4 · Change in ownershipJun 25, 2025Insider tradeSEC
4 · Change in ownershipJun 25, 2025Insider tradeSEC
4 · Change in ownershipJun 25, 2025Insider tradeSEC
4 · Change in ownershipJun 25, 2025Insider tradeSEC
3 · Initial statement of ownershipMay 23, 2025Insider tradeSEC
8-K · Current reportMay 19, 2025Current reportSEC
4 · Change in ownershipMay 14, 2025Insider tradeSEC
424B5 · ProspectusMay 12, 2025Offer documentSEC
8-K · Current reportMay 12, 2025ResultsSEC
10-Q · Quarterly reportMay 12, 2025Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeMay 7, 2025Big-stake noticeSEC
ARS · Annual report to shareholdersApr 30, 2025Annual reportSEC
DEF 14A · Proxy statementApr 29, 2025Meeting noticeSEC
8-K · Current reportApr 18, 2025Material contractSEC
8-K · Current reportApr 7, 2025Current reportSEC
8-K · Current reportMar 18, 2025ResultsSEC
S-8 · Registration statement for employee plansMar 17, 2025Offer documentSEC
10-K · Annual reportMar 17, 2025Annual reportSEC
8-K · Current reportMar 11, 2025Current reportSEC
8-K · Current reportMar 10, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
8-K · Current reportJan 31, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 13, 2025Big-stake noticeSEC
8-K · Current reportDec 10, 2024Current reportSEC
8-K · Current reportDec 3, 2024Current reportSEC
8-K · Current reportNov 27, 2024Current reportSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
8-K · Current reportNov 13, 2024ResultsSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportNov 4, 2024Current reportSEC
8-K · Current reportOct 30, 2024Current reportSEC
8-K · Current reportOct 16, 2024Current reportSEC
424B3 · ProspectusOct 11, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveOct 11, 2024Other filingsSEC
424B3 · ProspectusOct 10, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveOct 10, 2024Other filingsSEC
CORRESP · Letter to the SECOct 8, 2024Other filingsSEC
UPLOAD · Letter from the SECOct 8, 2024Other filingsSEC
S-3 · Registration statementOct 3, 2024Offer documentSEC
POS AM · Amendment to an effective registrationOct 3, 2024Offer documentSEC
8-K · Current reportOct 3, 2024Current reportSEC
424B3 · ProspectusOct 1, 2024Offer documentSEC
8-K · Current reportOct 1, 2024Current reportSEC
4 · Change in ownershipAug 27, 2024Insider tradeSEC
8-K · Current reportAug 15, 2024ResultsSEC
S-8 · Registration statement for employee plansAug 9, 2024Offer documentSEC
424B3 · ProspectusAug 9, 2024Offer documentSEC
10-Q · Quarterly reportAug 9, 2024Quarterly reportSEC
424B3 · ProspectusAug 1, 2024Offer documentSEC
8-K · Current reportAug 1, 2024Current reportSEC
8-K · Current reportJul 23, 2024Current reportSEC
424B3 · ProspectusJul 12, 2024Offer documentSEC
8-K · Current reportJul 12, 2024Current reportSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
424B3 · ProspectusJun 14, 2024Offer documentSEC
8-K · Current reportJun 14, 2024Meeting outcomeSEC
424B3 · ProspectusJun 6, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveJun 6, 2024Other filingsSEC
CORRESP · Letter to the SECJun 3, 2024Other filingsSEC
S-1/A · Registration statement, amendedMay 30, 2024Offer documentSEC
8-K · Current reportMay 20, 2024Material contractSEC
UPLOAD · Letter from the SECMay 16, 2024Other filingsSEC
8-K · Current reportMay 15, 2024ResultsSEC
10-Q · Quarterly reportMay 14, 2024Quarterly reportSEC
S-1 · Registration statementMay 10, 2024Offer documentSEC
DEF 14A · Proxy statementApr 29, 2024Meeting noticeSEC
8-K · Current reportApr 23, 2024Current reportSEC
SC 13G · Big-stake noticeApr 11, 2024Big-stake noticeSEC
8-K · Current reportApr 5, 2024ResultsSEC
8-K · Current reportApr 4, 2024Current reportSEC
10-K · Annual reportMar 29, 2024Annual reportSEC
8-K · Current reportMar 28, 2024Material contractSEC
8-K · Current reportMar 18, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedMar 6, 2024Big-stake noticeSEC
8-K · Current reportMar 5, 2024Current reportSEC
SC 13D/A · Big-stake notice, amendedFeb 28, 2024Big-stake noticeSEC
4 · Change in ownershipFeb 28, 2024Insider tradeSEC
8-K · Current reportFeb 28, 2024Material contractSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
4 · Change in ownershipFeb 13, 2024Insider tradeSEC
SC 13D · Big-stake noticeFeb 9, 2024Big-stake noticeSEC
3 · Initial statement of ownershipFeb 9, 2024Insider tradeSEC
8-K · Current reportFeb 7, 2024Management or board changeSEC
8-K · Current reportFeb 2, 2024Material contractSEC
4 · Change in ownershipJan 26, 2024Insider tradeSEC
4 · Change in ownershipJan 26, 2024Insider tradeSEC
4 · Change in ownershipJan 26, 2024Insider tradeSEC

This page holds 200 of 1,000 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from CervoMed Inc.’s releases · as of Nov 4, 2026

Common shares
15,128,540
Fully diluted
15,128,540

Fully diluted

LineSharesAs of
Common shares15,128,540Nov 4, 2026

Share count over time

CountShares
Nov 4, 202615,128,540

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Vanguard380K2.5%US$1.13MSep 30, 2026
Woodline Partners LP239K1.6%US$709KSep 30, 2026
Sabby Management, LLC200K1.3%US$593KSep 30, 2026
Geode Capital92,0070.61%US$273KSep 30, 2026
BlackRock79,6630.53%US$237KSep 30, 2026
Byrne Asset Management LLC50,0500.33%US$147KSep 30, 2026
Citigroup Inc39,3340.26%US$117KSep 30, 2026
Citizens Financial Group Inc37,4770.25%US$111KSep 30, 2026
Gsa Capital Partners LLP29,9920.20%US$89,000Sep 30, 2026
Savvy Advisors, Inc.25,9220.17%US$76,988Sep 30, 2026
All 34 holders
HolderSharesOf the companyValueAs of
Thompson Davis & Co., Inc.25,9000.17%US$76,926Sep 30, 2026
State Street20,5270.14%US$60,965Sep 30, 2026
Summit Financial, LLC18,1400.12%US$53,876Sep 30, 2026
Northern Trust13,3180.09%US$39,554Sep 30, 2026
Cetera Investment Advisers12,0730.08%US$35,857Sep 30, 2026
Caprock Group, LLC11,5850.08%US$34,407Sep 30, 2026
NFSG Corp11,5000.08%US$34,155Sep 30, 2026
HighTower Advisors, LLC11,2440.07%US$33,395Sep 30, 2026
Russell Investments Group, Ltd.8,1870.05%US$24,315Sep 30, 2026
Fidelity5,2720.03%US$15,658Sep 30, 2026
UBS2,5590.02%US$7,600Sep 30, 2026
Morgan Stanley2,5500.02%US$7,574Sep 30, 2026
Federation des caisses Desjardins du Quebec1,7000.01%US$5,049Sep 30, 2026
Osaic Holdings, Inc.1,5170.01%US$4,505Sep 30, 2026
RBC1,353<0.01%US$4,000Sep 30, 2026
Tower Research Capital LLC (TRC)1,318<0.01%US$3,914Sep 30, 2026
Hoey Investments, Inc1,080<0.01%US$3,208Sep 30, 2026
Nuveen733<0.01%US$4,607Sep 30, 2026
Nisa Investment Advisors, LLC145<0.01%US$431Sep 30, 2026
SBI Securities Co., Ltd.145<0.01%US$431Sep 30, 2026
BNP Paribas40<0.01%US$119Sep 30, 2026
Robinhood Markets, Inc.19<0.01%US$56Sep 30, 2026
Arax Advisory Partners5<0.01%US$15Sep 30, 2026
Danske Bank A/S1<0.01%US$3Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund250K1.7%US$776KJun 30, 2026
Vanguard Extended Market Index Fund66,0280.44%US$205KJun 30, 2026
Fidelity Extended Market Index Fund37,2410.25%US$116KMay 31, 2026
iShares Micro-Cap ETF19,5450.13%US$60,590Jun 30, 2026
Fidelity Total Market Index Fund9,0200.06%US$28,052May 31, 2026
Fidelity Series Total Market Index Fund8,9920.06%US$27,965May 31, 2026
Fidelity Nasdaq Composite Index Fund7,4110.05%US$23,048May 31, 2026
Avantis U.S. Small Cap Equity ETF3,2810.02%US$10,204May 31, 2026
1290 VT Micro Cap Portfolio1,068<0.01%US$3,311Jun 30, 2026

Insider trades

TradeTradeSharesPriceValueDate
Alam John J
Director, Officer: CEO & President, 10% owner
Buy23,681USD 1.51US$35,853Nov 18, 2026
Alam John J
Director, Officer: CEO & President, 10% owner
Buy76,319USD 1.53US$117KNov 18, 2026
Boger Joshua S
Director, 10% owner
Buy955,414USD 3.14US$3MJun 11, 2026

Big stakes

StakeStakeSharesDateFiling
BOGER JOSHUA S20.00%2.2MJun 11, 2026Schedule 13D
Armistice Capital, LLC9.53%1.59MJun 30, 2026Schedule 13G
Ra Capital Management, L.P.8.60%1.27MJun 30, 2026Schedule 13G
Woodline Partners LP5.10%689KJun 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Sol J. Barer
Other companies: Teva Pharmaceutical Industries Limited (Director · Since at least Jan 1, 2018); NexImmune, Inc. (Director · Feb 11, 2021 – Jul 5, 2023 · Past); Avalo Therapeutics, Inc. (Director · Feb 3, 2020 – Jun 15, 2021 · Past); PDS Biotechnology Corporation (Director · Sep 30, 2015 – Mar 15, 2019 · Past); Aevi Genomic Medicine LLC (Director · Jun 30, 2012 – Feb 3, 2020 · Past); InspireMD Inc. (Director · Jul 11, 2011 – Dec 7, 2016 · Past); Aegerion Pharmaceuticals Inc (Director · May 1, 2011 – Nov 29, 2016 · Past); Amicus Therapeutics Inc (Director · Jan 6, 2009 – Jun 9, 2016 · Past); Celgene Corporation (Director · Dec 31, 2005 – Jan 13, 2011 · Past)
Director · Nov 1, 2013 – Jul 24, 2014 · Past
Isaac Blech
Other companies: X4 Pharmaceuticals, Inc. (Director · Mar 13, 2019 – Mar 13, 2019 · Past); Aridis Pharmaceuticals Inc. (Director · Aug 13, 2018 – Aug 13, 2018 · Past); InspireMD Inc. (Director · Jan 22, 2016 – Dec 7, 2016 · Past); Avalo Therapeutics, Inc. (Director · Oct 14, 2015 – Dec 31, 2018 · Past); PDS Biotechnology Corporation (Director · Sep 30, 2015 – Mar 15, 2019 · Past); SpendSmart Networks Inc (Director · Aug 1, 2014 – Jul 19, 2016 · Past); Aevi Genomic Medicine LLC (Director · Nov 11, 2013 – Apr 15, 2016 · Past)
Director · Jul 24, 2014 – Aug 31, 2016 · Past
Phillip Donenberg
Other companies: Sensei Biotherapeutics, Inc. (Chair of the Audit Committee · Since at least Feb 13, 2026); Taysha Gene Therapies, Inc. (Director · Since at least Sep 23, 2020); Tectonic Therapeutic, Inc. (Director · Since at least Jun 20, 2018); Depomed Inc (SVP and CFO · Jul 16, 2018 – Jul 16, 2018 · Past); AveXis Inc (Chief Financial Officer · Oct 19, 2017 – May 15, 2018 · Past); ANI Pharmaceuticals, Inc. (Sr VP of Finance, CFO, Secy · Mar 16, 2006 – Jan 25, 2012 · Past)
Director · May 27, 2014 – Jul 24, 2014 · Past
Robert R. Ruffolo
Other companies: LB Pharmaceuticals Inc (Independent Director · Since at least Sep 10, 2025); Elicio Therapeutics, Inc. (Director · Since at least Jun 1, 2023); Sigilon Therapeutics Inc (Director · Dec 3, 2020 – Aug 11, 2023 · Past); Aridis Pharmaceuticals Inc. (Director · Aug 13, 2018 – Dec 5, 2022 · Past)
Director · Jun 29, 2017 – Jun 14, 2018 · Past
Alan Levin
Other companies: BioCryst Pharmaceuticals, Inc. (Director · Since at least Feb 27, 2020); Aceto Corporation (Director · Dec 5, 2013 – Oct 1, 2019 · Past); Pfizer, Inc. (Senior Vice President · Dec 30, 2005 – Sep 14, 2007 · Past)
Director · Jan 8, 2016 – Jul 1, 2021 · Past
Eric Francois
Other companies: 60 Degrees Pharmaceuticals, Inc. (Director · Since at least May 13, 2026); CERo Therapeutics Holdings, Inc. (Director · Since at least Feb 13, 2026); Scynexis, Inc. (Chief Financial Officer · Nov 1, 2015 – Jan 29, 2021 · Past)
Director · Jun 25, 2021 – Jul 1, 2021 · Past
Sylvie Grégoire
Other companies: Revvity, Inc. (Director · Feb 6, 2015 – May 15, 2023 · Past); Idm Pharma Inc (Director · Jun 14, 2006 – Jun 14, 2007 · Past); Cubist Pharmaceuticals Inc (Director · Jun 9, 2006 – Jun 10, 2010 · Past)
Co-Founder · Since at least Aug 16, 2023
Jeffrey V Poulton
Other companies: Alnylam Pharmaceuticals, Inc. (EVP, Chief Financial Officer · Since at least Aug 13, 2019); Q32 Bio Inc. (Director · Jul 21, 2020 – Jun 14, 2023 · Past)
Director · Since at least Aug 16, 2023
John Alam
Other companies: Pathfinder Cell Therapy Inc (Director · Sep 2, 2011 – Sep 2, 2011 · Past); Vertex Pharmaceuticals Incorporated (EVP, Med. Dev. Group & CMO · Dec 20, 2005 – Oct 1, 2008 · Past)
Co-Founder and Chief Executive Officer · Since at least Aug 16, 2023
Stephen M. Simes
Other companies: CytoDyn Inc. (Director · Since at least Oct 13, 2022); ANI Pharmaceuticals, Inc. (Vice Chairman, President & CEO, Director · Dec 14, 2007 – Jan 25, 2012 · Past)
Chief Executive Officer, Director · Mar 5, 2014 – Jul 24, 2014 · Past
All 40 people
PersonSeat
Frank Zavrl
Other companies: Puma Biotechnology Inc (Director · Sep 8, 2015 – Jun 9, 2020 · Past)
Director · Since at least Aug 16, 2023
Glenn Golenberg
Other companies: Grill Concepts Inc (Director · Jun 21, 2006 – Jun 12, 2008 · Past)
Director · Apr 30, 2009 – Apr 30, 2009 · Past
Jane H. Hollingsworth
Other companies: NuPathe Inc. (Chief Executive Officer, Director · Aug 5, 2010 – Mar 8, 2012 · Past)
Director · Since at least Sep 1, 2020
Jeff Poulton
Other companies: Alnylam Pharmaceuticals, Inc. (Chief Financial Officer · Since at least Nov 4, 2026)
Director · Since at least Nov 4, 2026
Joshua Boger
Other companies: Vertex Pharmaceuticals Incorporated (Director · Feb 2, 2006 – Jun 8, 2017 · Past)
Chair Of The Board · Since at least Feb 7, 2024
Kelly Blackburn
Other companies: aTyr Pharma, Inc. (VP, Clinical Affairs · May 6, 2015 – Mar 28, 2016 · Past)
Executive Vice President, Clinical Development · Since at least Aug 16, 2023
Matthew Winton
Other companies: Inozyme Pharma Inc (COO · Since at least Mar 13, 2024)
Chief Commercial and Business Officer · Since at least Oct 6, 2025
Rex Bright
Other companies: VYNE Therapeutics Inc. (Director · Jul 19, 2021 – Jul 19, 2021 · Past)
Director · Feb 5, 2014 – Jul 24, 2014 · Past
William Karl Hornung
Other companies: Hepion Pharmaceuticals, Inc. (Chief Financial Officer · Jun 23, 2014 – Jun 4, 2015 · Past)
Chief Financial Officer · Sep 21, 2018 – Jan 27, 2022 · Past
Ben ShealySr VP Finance & Treasurer · Jan 8, 2016 – Jan 2, 2018 · Past
Christopher D GallowayChief Medical Officer · Oct 19, 2020 – Jan 27, 2022 · Past
Craig AbolinVP of Research & Dev - Subsid. · Nov 18, 2013 – Jun 3, 2014 · Past
David G KalergisChairman and CEO, Director · Jan 8, 2016 – Jan 2, 2020 · Past
David QuigleySenior Partner · Since at least Oct 27, 2025
David Randolph JonesChief Medical Officer · Jan 8, 2016 – Jan 8, 2016 · Past
Diana M LanchoneyDirector · Jun 25, 2021 – Jun 30, 2023 · Past
Jill DavidsonDirector · Jul 26, 2023 – Sep 15, 2023 · Past
John William TannerChief Financial Officer · Aug 16, 2023 – Jan 26, 2024 · Past
Marco VerwijsExecutive Vice President, Technical Operations · Since at least Mar 4, 2026
Mark A WeinbergSr.V.P.- Clinical Development · Aug 4, 2014 – Aug 4, 2014 · Past
Mark De RoschExecutive Vice President, Regulatory and Government Affairs, and Program Management · Since at least May 1, 2025
Mark T GilesDirector · Jan 8, 2016 – Jul 1, 2021 · Past
Marwan SabbaghDirector · Since at least Aug 16, 2023
Mike Dunleavy SrDirector · Oct 15, 2009 – Oct 15, 2009 · Past
Nelson K StacksDirector · Nov 18, 2013 – Jul 24, 2014 · Past
PJ KelleherInvestor Relations · Since at least Dec 4, 2025
Robert Joseph Cobuzzi JrChief Operating Officer · Jan 7, 2020 – Feb 4, 2025 · Past
Robert W AdamsDirector · Jan 8, 2016 – Jul 1, 2021 · Past
Thomas E ByrneGeneral Counsel · Jan 8, 2016 – Jan 7, 2020 · Past
William ElderChief Financial Officer and General Counsel · Since at least Sep 22, 2020

Open People

Log in to ask 6ix AI your own questions about CervoMed Inc.